|
Qualigen Therapeutics, Inc. (QLGN) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Qualigen Therapeutics, Inc. (QLGN) Bundle
Unabhängig davon, ob Sie ein Investor oder Analyst sind, ist dieser (QLGN) DCF -Taschenrechner Ihr wesentliches Werkzeug für eine genaue Bewertung. Mit realen Daten von Qualigen Therapeutics, Inc. können Sie Prognosen anpassen und die Ergebnisse sofort beobachten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.6 | 4.3 | 5.7 | 5.0 | 5.2 | 5.2 | 5.2 | 5.3 | 5.3 | 5.3 |
| Revenue Growth, % | 0 | -22.52 | 31.29 | -11.85 | 4.44 | 0.33855 | 0.33855 | 0.33855 | 0.33855 | 0.33855 |
| EBITDA | -10.0 | -11.2 | -22.7 | -13.8 | -11.3 | -5.2 | -5.2 | -5.3 | -5.3 | -5.3 |
| EBITDA, % | -180.31 | -259.27 | -400.85 | -277.74 | -217.12 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .1 | .1 | .3 | .0 | .0 | .1 | .1 | .1 | .1 | .1 |
| Depreciation, % | 2 | 3.22 | 5.7 | 0.2441 | 0.08636334 | 2.25 | 2.25 | 2.25 | 2.25 | 2.25 |
| EBIT | -10.1 | -11.3 | -23.0 | -13.9 | -11.3 | -5.2 | -5.2 | -5.3 | -5.3 | -5.3 |
| EBIT, % | -182.32 | -262.49 | -406.55 | -277.98 | -217.2 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | .2 | 24.0 | 17.5 | 7.0 | .4 | 3.2 | 3.3 | 3.3 | 3.3 | 3.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .7 | .6 | .8 | .0 | .0 | .4 | .4 | .4 | .4 | .4 |
| Account Receivables, % | 12.73 | 14.3 | 14.55 | 0 | 0 | 8.31 | 8.31 | 8.31 | 8.31 | 8.31 |
| Inventories | .7 | 1.0 | 1.1 | 1.6 | .0 | .9 | .9 | .9 | .9 | .9 |
| Inventories, % | 11.88 | 22.14 | 18.68 | 31.83 | 0 | 16.9 | 16.9 | 16.9 | 16.9 | 16.9 |
| Accounts Payable | .9 | .5 | .9 | .6 | 2.2 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Accounts Payable, % | 15.82 | 11.63 | 15.68 | 12.43 | 42.71 | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 |
| Capital Expenditure | -.2 | -.2 | -.1 | -.3 | .0 | -.2 | -.2 | -.2 | -.2 | -.2 |
| Capital Expenditure, % | -3.5 | -4.88 | -2.5 | -6.4 | 0 | -3.46 | -3.46 | -3.46 | -3.46 | -3.46 |
| Tax Rate, % | -7.51 | -7.51 | -7.51 | -7.51 | -7.51 | -7.51 | -7.51 | -7.51 | -7.51 | -7.51 |
| EBITAT | -10.2 | -11.3 | -23.0 | -13.7 | -12.2 | -5.2 | -5.2 | -5.2 | -5.3 | -5.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -10.7 | -12.0 | -22.7 | -14.0 | -9.0 | -7.8 | -5.3 | -5.3 | -5.3 | -5.3 |
| WACC, % | 13.38 | 13.37 | 13.38 | 13.27 | 13.38 | 13.35 | 13.35 | 13.35 | 13.35 | 13.35 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -20.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -5 | |||||||||
| Terminal Value | -48 | |||||||||
| Present Terminal Value | -26 | |||||||||
| Enterprise Value | -46 | |||||||||
| Net Debt | 1 | |||||||||
| Equity Value | -47 | |||||||||
| Diluted Shares Outstanding, MM | 5 | |||||||||
| Equity Value Per Share | -9.32 |
What You Will Get
- Editable Forecast Inputs: Easily adjust key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Qualigen Therapeutics, Inc.’s (QLGN) financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A sleek Excel model tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as clinical trial success rates, market penetration, and R&D expenditures.
- Instant Valuation Metrics: Quickly computes intrinsic value, NPV, and additional financial outputs.
- High-Precision Accuracy: Relies on Qualigen Therapeutics' actual financial data for realistic valuation results.
- Effortless Scenario Analysis: Evaluate various assumptions and assess outcomes with ease.
- Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Qualigen Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Qualigen Therapeutics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Qualigen Therapeutics, Inc. (QLGN)?
- User-Friendly Interface: Perfect for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your specific analysis needs.
- Real-Time Feedback: Instantly view changes to Qualigen’s valuation as you tweak inputs.
- Preloaded Data: Comes with Qualigen’s current financial metrics for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for sound decision-making.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive and accurate valuation models for assessing investment opportunities in the biotech sector.
- Corporate Development Teams: Evaluate valuation scenarios to inform strategic decisions and partnerships.
- Consultants and Advisors: Deliver precise valuation insights for Qualigen Therapeutics, Inc. (QLGN) to clients.
- Students and Educators: Utilize current data to practice and teach financial modeling in the biotech industry.
- Biotech Enthusiasts: Gain insights into how companies like Qualigen Therapeutics, Inc. (QLGN) are valued within the market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Qualigen Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Qualigen Therapeutics, Inc. (QLGN).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.